An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function by Schlepckow, Kai et al.
Report
An Alzheimer-associated TREM2 variant occurs at
the ADAM cleavage site and affects shedding and
phagocytic function
Kai Schlepckow1, Gernot Kleinberger1,2 , Akio Fukumori3,†, Regina Feederle2,3,4,
Stefan F Lichtenthaler2,3,5,6, Harald Steiner1,3 & Christian Haass1,2,3,*
Abstract
Sequence variations occurring in the gene encoding the triggering
receptor expressed on myeloid cells 2 (TREM2) support an essential
function of microglia and innate immunity in the pathogenesis of
Alzheimer’s disease (AD) and other neurodegenerative disorders.
TREM2 matures within the secretory pathway, and its ectodomain is
shed on the plasma membrane. Missense mutations in the
immunoglobulin (Ig)-like domain such as p.T66M and p.Y38C retain
TREM2 within the endoplasmic reticulum and reduce shedding as
well as TREM2-dependent phagocytosis. Using mass spectrometry,
we have now determined the cleavage site of TREM2. TREM2 is shed
by proteases of the ADAM (a disintegrin and metalloproteinase
domain containing protein) family C-terminal to histidine 157, a
position where an AD-associated coding variant has been discovered
(p.H157Y) in the Han Chinese population. Opposite to the character-
ized mutations within the Ig-like domain, such as p.T66M and
p.Y38C, the p.H157Y variant within the stalk region leads to
enhanced shedding of TREM2. Elevated ectodomain shedding
reduces cell surface full-length TREM2 and lowers TREM2-dependent
phagocytosis. Therefore, two seemingly opposite cellular effects of
TREM2 variants, namely reduced versus enhanced shedding, result
in similar phenotypic outcomes by reducing cell surface TREM2.
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Introduction
Inflammation and activation of brain-resident immune cells are
common hallmarks of numerous neurological disorders. A pivotal
role of microgliosis has been recognized since a long time specifi-
cally in neurodegenerative disorders (Lyman et al, 2014; Villegas-
Llerena et al, 2016). A central role of microglial function in disease
pathogenesis is now further supported by the identification of
sequence variants and mutations in the triggering receptor
expressed on myeloid cells 2 (TREM2) that are associated with an
increased risk for several neurodegenerative disorders such as
Alzheimer’s disease (AD), frontotemporal lobar degeneration
(FTLD), Parkinson’s disease, and FTLD-like syndrome (Guerreiro &
Hardy, 2013; Guerreiro et al, 2013; Jonsson & Stefansson, 2013;
Rayaprolu et al, 2013; Borroni et al, 2014; Cady et al, 2014; Cuyvers
et al, 2014) and in a homozygous state cause Nasu–Hakola disease
(Klunemann et al, 2005). In the brain, TREM2 is preferentially
expressed in microglia and is functionally required for migration,
cytokine release, phagocytosis, lipid sensing, ApoE binding, shield-
ing of amyloid plaques, and microglia proliferation (Kleinberger
et al, 2014; Atagi et al, 2015; Bailey et al, 2015; Colonna & Wang,
2016; Ulrich & Holtzman, 2016; Yeh et al, 2016; Yuan et al, 2016).
TREM2 is a type-1 transmembrane protein that shuttles to the
plasma membrane where it exerts its cell autonomous biological
functions. TREM2 undergoes regulated intramembrane proteolysis
(RIP) (Lichtenthaler et al, 2011; Wunderlich et al, 2013) (Fig 1A),
which is initiated on the cell surface via shedding of full-length
TREM2 by ADAM10 (a disintegrin and metalloproteinase domain
containing protein) (Kleinberger et al, 2014). Shedding by ADAM10
results in the liberation of soluble TREM2 (sTREM2), which can be
detected in human cerebrospinal fluid (CSF) (Kleinberger et al,
2014; Heslegrave et al, 2016; Piccio et al, 2016; Suarez-Calvet et al,
2016a,b). The membrane-retained C-terminal fragment (CTF) is
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subsequently cleared via an intramembranous cleavage by
c-secretase (Fig 1A) (Wunderlich et al, 2013; Glebov et al, 2016).
So far several mutations have been functionally investigated. Muta-
tions within the immunoglobulin (Ig)-like domain such as p.T66M
and p.Y38C apparently result in misfolding of TREM2 and reten-
tion of the immature protein within the endoplasmic reticulum
(Kleinberger et al, 2014; Park et al, 2015; Song et al, 2017) although
upon strong transient overexpression mutant proteins may escape
retention (Kober et al, 2016). As a consequence of misfolding,
reduced cell surface levels of TREM2 are observed and shedding is
dramatically lowered leading to reduced sTREM2 and TREM2 CTF
levels (Kleinberger et al, 2014). Consistent with that, a patient with
a homozygous TREM2 p.T66M mutation had extremely low or even
no detectable sTREM2 in the CSF (Kleinberger et al, 2014; Piccio
et al, 2016). Lowered cell surface TREM2 results in reduced phago-
cytic activity (Kleinberger et al, 2014). Although initially discrepant
results regarding the effects of a loss of TREM2 function on amyloid
plaque pathology were reported (Jay et al, 2015; Wang et al, 2015),
TREM2 loss of function may lead to the accumulation of fuzzy
amyloid plaques suggesting a lack of phagocytic clearance of the
plaque halo or reduced prevention of amyloid plaque growth (Wang
et al, 2016; Yuan et al, 2016). In support of reduced phagocytic
plaque degradation, we showed recently that immunotherapeutic
clearance of amyloid plaques via phagocytosis is reduced in the
absence of TREM2 (Xiang et al, 2016).
Most of the functionally investigated mutations are located
within the Ig-like domain of TREM2. Misfolding of this domain,
retention, and consequently reduced shedding appear to be a
common readout of at least some of these variants. Although many
sequence variants were found within the Ig-like domain, genetic
studies also identified sequence variants within the stalk region and
such mutants are unlikely to affect folding of the Ig-like domain.
Since mutations in the stalk region may affect the efficacy and preci-
sion of ADAM-mediated shedding, we first determined the TREM2
cleavage site. Strikingly, ADAM-mediated cleavage within the stalk
region occurs C-terminal to histidine 157 exactly where the AD-asso-
ciated variant p.H157Y is located (Guerreiro et al, 2013; Ma et al,
2014; Jiang et al, 2016; Song et al, 2017). Analysis of proteolytic
processing of the mutant variant revealed that higher levels of
sTREM2 are generated, a finding opposite to the reduced shedding
observed for mutations within the Ig-like domain such as p.T66M
and p.Y38C (Kleinberger et al, 2014). However, enhanced shedding
of TREM2 p.H157Y leads to reduced cell surface full-length TREM2
and hence to reduced phagocytic activity. Thus, mutations located
within the Ig-like domain or the stalk region reduce surface expres-
sion of TREM2 and probably its signaling activity via completely dif-
ferent cellular mechanisms.
Results and Discussion
TREM2 is cleaved by ADAM proteases between histidine 157 and
serine 158
To determine the cleavage site of TREM2, we followed two indepen-
dent approaches. First, we determined the N-terminus of the
membrane retained CTF remaining after shedding of the full-length
precursor (Kleinberger et al, 2014). To do so, we expressed
C-terminally Flag-tagged TREM2 (TREM2-CFlag) in human kidney
293 cells (HEK 293) (strategy I; Fig 1B). We enriched for the ADAM
generated TREM2 CTF by inhibiting its c-secretase-mediated
intramembrane cleavage with DAPT (Dovey et al, 2001). Consistent
with previous results (Wunderlich et al, 2013), Western blot analy-
sis revealed a massive accumulation of the CTF upon c-secretase
inhibition (Fig 1C). Immunoprecipitation followed by mass spec-
trometry of the DAPT enriched CTF revealed one major peak corre-
sponding to a molecular mass of 8,841.48 Da (Fig 1D; Table 1).
This corresponds to a CTF with an N-terminus at serine 158 (see
also Fig 1J). Additional very minor peaks may be due to proteolytic
degradation of the CTF most likely within lysosomes. This is
◀ Figure 1. TREM2 is shed at a single cleavage site in the ectodomain between histidine 157 and serine 158.A Regulated intramembrane proteolysis of TREM2. ADAM10 initiates proteolytic processing of TREM2 by liberating its ectodomain (sTREM2). Subsequent processing of
the membrane retained C-terminal fragment (CTF) by c-secretase within the transmembrane domain (TM) releases the intracellular domain (ICD) into the cytosol. A
short p3-like peptide (Haass et al, 1993) may be secreted.
B Outline of strategy I for mass spectrometric (MS) determination of the N-terminal end of the TREM2 CTF enriched upon c-secretase inhibition using DAPT.
C Western blot analysis of TREM2 stably expressed in HEK293 Flp-In cells upon c-secretase inhibition using DAPT. Application of DAPT leads to a robust accumulation
of the TREM2 CTF under constitutive conditions as well as upon phorbol 12-myristate 13-acetate (PMA) mediated stimulation of TREM2 ectodomain shedding. The
TREM2 9D11 antibody raised against the TREM2 C-terminus was used to detect TREM2, and calnexin levels were analyzed as a loading control. Here, as in all other
Western blots in Figs 1 and 2, the two lanes represent samples from two separate wells seeded at the same time.
D MALDI-TOF MS determination of the ectodomain cleavage site by immunoprecipitation of TREM2 CTF. The peak at 8,841.48 Da corresponds to a single cleavage site between
histidine 157 and serine 158. Very minor additional peaks may represent cellular degradation products, as the N-terminal counterpart cannot be observed (see Fig 1I).
E Stimulation of ectodomain shedding by PMA leads to strong increases in sTREM2 (anti-HA, upper panel) and sAPPa (2D8, lower panel). DMSO served as a vehicle
control. EV, empty vector control.
F MALDI-TOF MS determination of the ectodomain cleavage site upon ADAM17 stimulation using PMA. TREM2 CTFs were enriched by c-secretase inhibition using
DAPT (Fig 1C). The peak at 8,837.09 Da corresponds to a single cleavage site between histidine 157 and serine 158.
G Outline of strategy II for MS determination of the C-terminal end of sTREM2 generated by ectodomain shedding.
H Western blot analysis of full-length TREM2-TEVFlag (middle panel) and ectodomain shedding (upper panel) upon transient transfection of HEK293 Flp-In cells.
EV, empty vector control.
I MALDI-TOF MS determination of the ectodomain cleavage site following the strategy outlined in Fig 1G. The peak at a mass of 3,947.78 Da corresponds to cleavage
C-terminal of histidine 157 and is absent in cells transfected with an empty expression vector.
J TREM2 is shed predominantly C-terminal to histidine 157 as observed in two different cell types as well as under constitutive and PMA-stimulated conditions.
K Western blot analysis of full-length TREM2-TEVFlag (middle panel) and ectodomain shedding (upper panel) upon transient transfection of THP-1 monocytes.
L MALDI-TOF MS determination of the ectodomain cleavage site in THP-1 monocytes following the strategy outlined in Fig 1G. The peak at a mass of 3,943.80 Da
corresponds to cleavage C-terminal of histidine 157 and is absent in cells transfected with an empty expression vector.
Source data are available online for this figure.
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supported by the almost complete absence of such minor peaks in
the analysis of the cleavage site of sTREM2 (see below).
So far ADAM10 has been described as the sole sheddase of
TREM2 (Kleinberger et al, 2014). However, shedding is well known
to be stimulated after protein kinase C activation. Under these
conditions, shedding is predominantly performed by ADAM17
(Black, 2002; Saftig & Lichtenthaler, 2015). To prove whether
TREM2 shedding can be stimulated similarly and whether cleavage
still occurs at the same site, we treated HEK293 cells stably express-
ing TREM2-CFlag with phorbol 12-myristate 13-acetate (PMA). This
resulted in a robust increase in TREM2 shedding (Fig 1E). Similarly,
and in line with previous results (Nitsch et al, 1992), shedding of
the amyloid precursor protein (APP) was also stimulated (Fig 1E;
lower panel). To determine the cleavage site of TREM2 after PMA-
stimulated shedding, we again enriched for the CTF by c-secretase
inhibition (Fig 1C) followed by immunoprecipitation with an anti-
Flag antibody. Mass spectrometry of the CTF revealed one major
peak corresponding to a molecular mass of 8,837.09 Da (Fig 1F;
Table 1). Thus, after PMA-stimulated TREM2 shedding, the prote-
olytic cleavage also occurs between histidine 157 and serine 158
(see also Fig 1J).
To independently confirm the cleavage site, we introduced a
TEV-protease cleavage site within the ectodomain of TREM2 after
amino acid 132 followed by a Flag-tag (TREM2-TEVFlag; strategy II;
Fig 1G) according to our previously described strategy for the identi-
fication of the cleavage site of presenilins (Fukumori et al, 2010).
We first proved that such a modified TREM2 variant matures and
undergoes shedding like unmodified TREM2. In cell lysates, full-
length TREM2-TEVFlag was readily detected (Fig 1H; middle panel).
HEK 293 cells expressing TREM2-TEVFlag also showed robust shed-
ding of TREM2-TEVFlag (Fig 1H; upper panel), which is in line with
the detection of the CTF in cell lysates (Fig 1H; middle panel). Next,
sTREM2 was isolated by immunoprecipitation with an anti-Flag
antibody and subsequently digested with TEV protease. Upon
enrichment of the cleaved C-terminal peptide by anti-Flag immuno-
precipitation (see Fig 1G), mass spectrometric analysis revealed a
single sharp peak corresponding to a molecular mass of
3,947.78 Da, which was absent in conditioned media from HEK293
cells transfected with an empty expression vector (Fig 1I; Table 1).
The observed molecular mass corresponds to a peptide terminating
within the stalk region after histidine 157 (see also Fig 1J). Thus,
both strategies independently identified one major cleavage site
between histidine 157 and serine 158 (Fig 1J).
Next, we investigated whether shedding also occurs in a human
monocytic cell line at the same site. To do so, we transiently trans-
fected TREM2-TEVFlag into THP-1 cells (Tsuchiya et al, 1980).
TREM2-TEVFlag matures in THP-1 cells as in HEK293 cells and
shedding of sTREM2 occurs as expected (Fig 1K). Following the
same strategy as for HEK293 cells (see Fig 1G), mass spectrometric
analysis revealed a single sharp peak corresponding to a molecular
mass of 3,943.80 Da (Fig 1L; Table 1), which was absent in condi-
tioned media from THP-1 cells transfected with an empty expression
vector (Fig 1L; Table 1). The observed molecular mass corresponds
to a peptide terminating within the stalk region after histidine 157
(see also Fig 1J), indicating the same TREM2 cleavage site in a
human monocytic cell line.
A disease-associated mutation at the cleavage site
increases shedding
The cleavage site of TREM2 after histidine 157 coincides with the
p.H157Y late-onset AD-associated mutation recently described in
the Han Chinese population (Ma et al, 2014; Jiang et al, 2016)
(Fig 2A). Since it is well known that an AD-related mutation at the
site of b-secretase-mediated shedding of APP pathologically affects
APP proteolysis (Citron et al, 1992; Cai et al, 1993; Haass et al,
1995b; Thinakaran et al, 1996), we investigated proteolytic process-
ing of TREM2 p.H157Y. Surprisingly, and opposite to the p.T66M
and p.Y38C mutations, we found enhanced shedding of the p.H157Y
mutant by Western blotting (Fig 2B). This was independently con-
firmed by anti-HA ELISA-mediated quantitation (Fig 2C). Since
shedding of p.H157Y is significantly increased and the amino acid
sequence is changed at the P1 site, we next asked whether the cleav-
age still occurs after amino acid 157. As described above, we
enriched for the CTF produced from TREM2 p.H157Y via inhibition
of c-secretase by DAPT (see also Fig 2H). Mass spectrometry of the
enriched CTF revealed one major peak corresponding to a molecular
mass of 8,832.76 Da, which is consistent with a predominant cleav-
age after amino acid 157 (Fig 2D and E; Table 1). Thus, TREM2
p.H157Y is cleaved at the very same position as wild-type (wt)
TREM2. Furthermore, TREM2 p.H157Y is also shed by members of
the ADAM family, since the protease inhibitors GM6001 and
GI254023X significantly reduce shedding (Fig 2F). Enhanced shed-
ding of the p.H157Y variant is accompanied by reduced levels of
mature fully glycosylated TREM2 (Fig 2G). Despite increased shed-
ding and reduced mature TREM2, we surprisingly observed less
CTFs suggesting enhanced degradation (Fig 2G). In line with that,
the CTF derived from TREM2 p.H157Y is recovered after inhibition
of c-secretase cleavage (Fig 2H). Furthermore, additional expression
of DAP12, which forms a tight complex with TREM2 (Paradowska-
Gorycka & Jurkowska, 2013), prevents c-secretase-dependent degra-
dation of the p.H157Y TREM2 CTF (Fig. 2I). Enhanced shedding
Table 1. Summary of identified peptides and comparison of observed masses to calculated masses. [M + H]+ indicates a singly charged peptide.
Peptide Cleavage Sequence
Mass [M + H]+ (Da)
Calculated Observed
TREM2-CFlag WT (HEK) N-terminal of serine 158 (P10) SISRSLLEGEIPF. . .DYKDDDDK 8,840.08 8,841.48
TREM2-CFlag WT (PMA, HEK) N-terminal of serine 158 (P10) SISRSLLEGEIPF. . .DYKDDDDK 8,840.08 8,837.09
TREM2-CFlag p.H157Y (HEK) N-terminal of serine 158 (P10) SISRSLLEGEIPF. . .DYKDDDDK 8,840.08 8,832.76
TREM2-TEVFlag (HEK) C-terminal of histidine 157 (P1) GDYKDDDDKLDHRDAGDLWFPGESESFEDAHVEH 3,948.01 3,947.78
TREM2-TEVFlag (THP-1) C-terminal of histidine 157 (P1) GDYKDDDDKLDHRDAGDLWFPGESESFEDAHVEH 3,948.01 3,943.80
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suggests reduced levels of TREM2 on the plasma membrane. Levels
of cell surface mutant and wt TREM2 were determined by cell
surface biotinylation. In line with our previous findings (Kleinberger
et al, 2014), wt TREM2 was readily observed on the plasma
membrane (Fig 2J). In contrast, p.H157Y could not be biotinylated
on the cell surface similar to the previously investigated p.T66M
mutant (Kleinberger et al, 2014) (Fig 2I). Thus, the histidine-to-tyro-
sine exchange at amino acid 157 increases shedding of mutant
TREM2 and, as a consequence, reduces cell surface levels of the
fully mature protein.
The disease-associated mutation reduces phagocytic activity
Both the p.T66M and the p.H157Y mutations lead to reduced cell
surface TREM2, albeit via opposite cellular mechanisms. Since the
amount of cell surface TREM2 correlates with its cell autonomous
function (Kleinberger et al, 2014; Song et al, 2017), we hypothesized
that both mutations may result in a similar loss of function. To inves-
tigate TREM2-mediated function, we analyzed TREM2-dependent
phagocytosis. In line with our previous findings (Kleinberger et al,
2014), wt TREM2 readily promoted uptake of Escherichia coli conju-
gated to pHrodo (Fig 3). Uptake was specific since treatment with
cytochalasin D blocked engulfment of E. coli. Strikingly, cells
expressing TREM2 p.H157Y exhibited a significantly reduced phago-
cytic capacity (Fig 3), demonstrating that this mutation at least
affects phagocytic uptake of bacteria.
Sequence variations of TREM2 have been found in all domains of
the protein. However, most of the mutations occur within the Ig-like
domain. At least some of the mutant proteins, such as p.T66M and
p.Y38C, are likely to be misfolded and retained within the endoplas-
mic reticulum (Kleinberger et al, 2014; Park et al, 2015; Song et al,
2017). Therefore, these types of mutations reduce cell surface
TREM2 and consequently the release of sTREM2, as shedding
predominantly occurs on the plasma membrane. Consistent with
reduced cell surface TREM2, biological functions of TREM2 such as
lipid sensing, ApoE binding, and phagocytosis are all decreased by
such mutations (Kleinberger et al, 2014; Atagi et al, 2015; Bailey
et al, 2015; Yeh et al, 2016). Thus, for this class of mutations
reduced release of sTREM2 may serve as a surrogate marker for
◀ Figure 2. A TREM2 sequence variant at the cleavage site leads to an increased shedding.A The TREM2 variant p.H157Y is located at the P1 site where shedding occurs via proteases of the ADAM family. In addition, the location of the p.T66M mutation within
the Ig-like V-type domain is indicated.
B Increased shedding of TREM2 p.H157Y. Western blot analysis of conditioned media of HEK293 Flp-In cells stably transfected with cDNAs encoding HA and Flag-tagged wt
TREM2 or TREM2 p.T66M and p.H157Y. Anti-HA antibody was used for detecting TREM2, and sAPPa levels were analyzed as a loading control. EV, empty vector control.
C ELISA-mediated quantitation of sTREM2 (Suarez-Calvet et al, 2016a) in conditioned media from HEK293 cells stably expressing wt TREM2 or TREM2 p.T66M and
p.H157Y. Error bars indicate SEM of seven independent experiments. One-way ANOVA (with Dunnett’s post hoc test against wt) was used for statistical analysis; wt
versus EV: ***P < 0.0001; wt versus p.T66M: ***P < 0.0001; wt versus p.H157Y: **P = 0.002.
D MALDI-TOF MS analysis of the CTF derived from shedding of TREM2 p.H157Y identifies a single peak at a mass of 8,832.76 Da corresponding to a single cleavage site
between tyrosine 157 and serine 158.
E TREM2 p.H157Y is shed predominantly C-terminal to tyrosine 157.
F Western blot analysis of TREM2 ectodomain shedding in the presence and absence of ADAM protease inhibitors. In line with previous findings (Kleinberger et al,
2014), the broad ADAM inhibitor (GM6001; left panel) and the more selective ADAM10 inhibitor (GI254023X; right panel) reduce shedding of wt TREM2, TREM2
p.H157Y as well as sAPPa.
G Western blot analysis of membrane fractions of HEK293 Flp-In cells stably expressing wt TREM2, TREM2 p.T66M, or TREM2 p.H157Y. The TREM2 9D11 antibody raised
against the TREM2 C-terminus was used to detect TREM2, and calnexin levels were analyzed as a loading control.
H Western blot analysis of membrane fractions derived from cells stably expressing wt TREM2, TREM2 p.T66M, and TREM2 p.H157Y. c-Secretase inhibition allows robust
accumulation of the TREM2 CTF after shedding of TREM2 p.H157Y. Calnexin levels were analyzed as a loading control.
I Western blot analysis of membrane fractions derived from cells stably expressing wt TREM2, TREM2 p.T66M, and TREM2 p.H157Y together with or without transiently
expressed human DAP12. Note that co-expression of human DAP12 allows the recovery of large amounts of the TREM2 p.H157Y CTF. Calnexin levels were analyzed as
a loading control.
J Western blot analysis of cell surface biotinylated TREM2 reveals dramatically reduced levels of surface-exposed TREM2 p.H157Y, whereas robust amounts of cell
surface wt TREM2 are detected. The anti-HA antibody was used to detect TREM2.
Source data are available online for this figure.
Figure 3. The TREM2 variant p.H157Y impairs phagocytosis.
Phagocytic activity was measured using an E. coli pHrodo uptake assay. Cells
were incubated with E. coli pHrodo particles for either 1 or 2 h (gray and black
bars, respectively), and populations of phagocytically active cells were
determined using flow cytometry. Cytochalasin D was used as a control. Data are
shown as mean  SD from four independent experiments (nEV(1 h) = 11,
nWT(1 h) = 11, nEV(2 h) = 12, nWT(2 h) = 12) and three and two independent
experiments for 1- and 2-h treatments, respectively (np.H157Y(1 h) = 8,
np.H157Y(2 h) = 6). One-way ANOVA (with Tukey’s post hoc test) was used for
statistical analysis; EV versus WT (1 h): ***P = 0.0005; EV versus p.H157Y (1 h):
P = 0.413; WT versus p.H157Y (1 h): *P = 0.0141; EV versus WT (2 h):
***P = 0.000014; EV versus p.H157Y (2 h): P = 0.071; WT versus p.H157Y (2 h):
**P = 0.0031.
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reduced biological function. In line with that, a patient with a
homozygous p.T66M mutation showed almost no sTREM2 in
plasma and cerebrospinal fluid (Kleinberger et al, 2014; Piccio et al,
2016), and this mutation is known to severely affect TREM2 func-
tions (Kleinberger et al, 2014; Yeh et al, 2016). A number of
sequence variants are now reported to occur within the stalk region
of TREM2, which may not be involved in ligand binding and may
also not be as sensitive to subtle structural changes as the highly
folded Ig-like domain (Paradowska-Gorycka & Jurkowska, 2013).
This region apparently serves as a spacer for the functionally impor-
tant Ig-like domain but also contains the cleavage site recognized by
the TREM2 sheddase that we have identified between histidine 157
and serine 158. Strikingly, a mutation, which increases the risk for
late-onset AD, occurs in the Han Chinese population at P1 of the
cleavage site (p.H157Y) (Ma et al, 2014; Jiang et al, 2016). In
contrast to the above-described mutation, the p.H157Y mutation
does not decrease but rather enhances shedding. On the first view,
this may be a rather paradoxical finding. However, we also
observed much less mature TREM2 p.H157Y, and consequently, the
mutant protein could not be surface biotinylated similar to
the TREM2 p.T66M mutation. Thus, enhanced shedding reduces the
amount of full-length membrane-bound TREM2 on the cell surface.
Apparently, the p.H157Y mutation provides a better substrate for
shedding. As a consequence, shedding may already take place
during transport of mutant TREM2 to the plasma membrane. This
would be very similar to the Swedish APP mutation, which provides
a better substrate for b-secretase-mediated processing and is
therefore cleaved much earlier during cell surface transport than its
wild-type counterpart (Haass et al, 1995b; Thinakaran et al, 1996).
Moreover, ADAMs do not only cleave at the cell surface, but can
also process their substrates (e.g. APP) already within the trans-
Golgi (Haass et al, 1995a). For TREM2-mediated signaling, cell
surface TREM2 bound to its co-receptor DAP12 is an absolute
prerequisite (Colonna & Wang, 2016); thus, reduced cell surface
TREM2 should result in reduced biological activity. This is indeed
what we observed for the p.H157Y mutation. Similar to the p.T66M
mutation (Kleinberger et al, 2014), this mutation interferes with
phagocytosis and probably with all other surface TREM2-related
functions as well. In line with that Song et al (2017) report, reduced
ligand binding of p.H157Y and reduced phagocytic function may
directly affect AD pathology. In that regard, it has been shown
recently that in the absence of TREM2 fuzzy amyloid plaques accu-
mulate, which may be a consequence of reduced engulfment of
amyloid b-peptide by the dysfunctional microglia (Wang et al,
2016). Whether this is due to a direct inhibition of phagocytic activ-
ity and/or reduced migration to amyloid plaques remains to be
shown. Moreover, similar to our recent analysis of mice endoge-
nously expressing p.T66M (Kleinberger et al, 2017), the p.H157Y
mutation should also be functionally investigated under an in vivo
setting to confirm mutant TREM2 function in microglia in their natu-
ral environment.
Taken together, by locating a late-onset AD-associated TREM2
mutation right at P1 of the ADAM cleavage site, we demonstrate a
novel cellular mechanism, which via enhanced shedding may lead
to reduced function. Furthermore, our findings may open the oppor-
tunity to therapeutically modulate TREM2 function by selectively
blocking access of ADAM proteases to the cleavage site between
histidine 157 and serine 158.
Materials and Methods
cDNA constructs
cDNA constructs that were used in this study have been previously
described (Kleinberger et al, 2014). Briefly, TREM2-CFlag as
denoted in the main text is full-length TREM2 with N- and C-term-
inal HA and Flag tags, respectively. TREM2-DAP12 fusion constructs
contained the ectodomain of TREM2 including aa169 (Proline169)
fused to DAP12 (aa28–113). Furthermore, an amino acid change in
the transmembrane domain of DAP12 from aspartic acid to alanine
(p.D50A) was included (Hamerman et al, 2006). Additionally, the
TREM2-DAP12 fusion constructs included a HA-tag and a linker
sequence (SGGGGGLE) after the endogenous TREM2 signal peptide.
The TREM2 missense mutation p.H157Y (CAC>TAC) was intro-
duced into the respective plasmid by site-directed mutagenesis
(Stratagene). The TREM2-TEVFlag construct was generated accord-
ing to a previously reported strategy (Fukumori et al, 2010). The
TEVFlag sequence (ENLYFQGDYKDDDDK) was introduced after
amino acid 132. All constructs were verified by DNA sequencing
(GATC Biotech).
Cell culture
Generation and maintenance of stable HEK293 Flp-In cells lines
were performed as previously described (Kleinberger et al, 2014).
Human monocytic THP-1 cells were cultured in RPMI1640 medium
supplemented with 10% FCS (Sigma), 1% penicillin/streptomycin,
and 50 lM b-mercaptoethanol. THP-1 cells were kept in culture at
densities between 2 × 105 and 1 × 106 cells per ml of cell culture
medium, and transfections were performed at densities between
5 × 105 and 1 × 106 cells per ml of cell culture medium. Transfec-
tions were carried out with 1 lg of TREM2-TEVFlag DNA per
1 × 106 of THP-1 cells using a nucleofector device and the SG Cell
Line 4D-Nucleofector X Kit (both Lonza). GFP cDNA was trans-
fected in parallel to check for transfection efficiency. Transient
transfection of cells stably expressing wt or mutant TREM2 with
human DAP12 was performed in a 6-well plate using 2 lg DNA/well
and Lipofectamine 2000. If not stated otherwise, cell culture
reagents were purchased from Thermo Fisher Scientific.
Antibodies
For immunoblot detection, the following antibodies were used: rat
monoclonal anti-HA conjugated to HRP (3F10; 1:700 to 1:2,000;
Roche), goat polyclonal anti-human TREM2 (AF1828; 1:100; R&D
Systems), rat monoclonal antibody against a C-terminal peptide of
human TREM2 (9D11; 1:20; C-HGQKPGTHPPSELDCGHDPG), rat
monoclonal antibody against sAPPa (2D8 (Shirotani et al, 2007);
1:100), and rabbit anti-calnexin (1:3,000, Enzo Life Sciences). The
HRP-conjugated goat anti-rat (1:10,000; Santa Cruz Biotechnology),
donkey anti-goat (1:10,000; Santa Cruz Biotechnology), and goat anti-
rabbit IgG (1:10,000; Promega) were used as secondary antibodies.
Cell surface biotinylation
Surface biotinylations were carried out as described previously
(Kleinberger et al, 2014).
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Preparation of conditioned media, cell lysates,
and immunoblotting
HEK293 Flp-In cells stably expressing respective cDNA constructs
were seeded at a density of 1.5 × 106/cm2, and medium was
changed 48 h post-seeding. Inhibitors/activators used were GM
6001 (25 lM), GI 254023X (5 lM), DAPT (5 lM, all Sigma), and
phorbol 12-myristate 13-acetate (PMA; 100 nM; Enzo Life Sciences).
Conditioned medium was collected after 18–20 h except for PMA-
treated cells where media were collected after 2 h. Membrane frac-
tions were prepared as previously described (Kleinberger et al,
2014). Alternatively, total lysates were prepared using STE lysis
buffer (150 mM NaCl, 50 mM Tris/HCl pH 7.6, 2 mM EDTA, 1%
Triton X-100). Lysis was carried out on ice for 20 min, and lysates
were obtained upon centrifugation at 15,871 g for 30 min at 4°C. To
generate lysates upon transient transfection of THP-1 monocytes,
cells were gently centrifuged (100 g for 10 min at 4°C) after over-
night incubation at 37°C, washed once with ice-cold phosphate-
buffered saline (PBS), centrifuged again (100 g for 10 min at 4°C),
and subsequently lysed. Protein concentrations were measured
using the BCA method, equal amounts of protein were mixed with
Laemmli sample buffer supplemented with b-mercaptoethanol,
separated by standard 15% SDS–PAGE, transferred onto polyvinyli-
dene difluoride membranes (Hybond P; Amersham Biosciences),
processed with respective antibodies, and developed using
enhanced chemiluminescence technique (Pierce).
Phagocytosis assay
Phagocytosis of fluorogenic E. coli particles (pHrodo Green, Molecu-
lar Probes) after 60- or 120-min incubation at 37°C was performed
as described before (Kleinberger et al, 2014). As a negative control,
phagocytosis was inhibited with cytochalasin D (10 lM; Sigma).
sTREM2 ELISA
sTREM2 levels from conditioned media were essentially determined
as previously described (Kleinberger et al, 2014). Rat anti-HA anti-
body (3F10; 1:1,000; Roche) was used as detection antibody.
MALDI-TOF mass spectrometry analysis of ectodomain cleavage
For the identification of the N-terminus of the TREM2 CTF, HEK293
Flp-In cells stably expressing TREM2-CFlag (both wt and p.H157Y)
were harvested in ice-cold PBS upon overnight treatment using
DAPT. Upon treatment with PMA, cells were harvested 5 h post-
treatment. Cell pellets were frozen at 20°C until use. Cells were
lysed in lysis buffer (4% n-dodecyl b-D-maltoside, 0.1% N-octylglu-
coside, 10 mM Tris–HCl, pH 8.0, 5 mM EDTA, and 140 mM NaCl)
containing protease inhibitor mix (Sigma) for 20 min on ice. Follow-
ing a clarifying spin at 21,000 g for 10 min, supernatants were
subjected to a second clarifying spin by ultracentrifugation at
100,000 g for 1 h and incubated with anti-FLAG M2-agarose (Sigma)
overnight by rotation at 4°C. Beads were washed four times with
immunoprecipitation/mass spectrometry (IP/MS) buffer (0.1% N-
octylglucoside, 10 mM Tris–HCl, pH 8.0, 5 mM EDTA, and 140 mM
NaCl) and two times with water. Beads were stored at 20°C until
MS analysis. Control samples were generated using HEK293 Flp-In
cells stably transfected with an empty expression vector (pcDNA5/
FRT/TO, Thermo Fisher Scientific).
For the identification of the C-terminus of the shed ectodomain,
the TREM2-TEVFlag cDNA construct was transfected transiently
into HEK293 Flp-In cells followed by addition of fresh medium 24 h
post-transfection. After further 5 h, the supernatant was collected
and cleared by centrifugation at 15,000 g for 30 min at 4°C. The pH
of the supernatant was adjusted to pH 8.0 using 1 M Tris/HCl
(30 mM final concentration). 0.5 M EDTA pH 8.0 (3.5 mM final
concentration) was added, and the supernatant was incubated with
40 ll anti-FLAG M2-agarose overnight by rotation at 4°C. Beads
were washed four times with IP/MS buffer and two times with
water. The TREM2 ectodomain was eluted from the beads with
40 ll 100 mM glycine pH 2.5 for 10 min by rotation at 4°C. Upon
centrifugation (5 min at 1,200 g), the supernatant was neutralized
by addition of 1/8 volume 1 M Tris–HCl pH 8.0. After addition of
EDTA, DTT (final concentrations of 5 mM and 1 mM, respectively),
and complete protease inhibitor (Roche), 10 units of AcTEV
protease (Thermo Fisher Scientific) were added and digestion was
carried out overnight at 4°C. Upon addition of 1 ml of IP/MS buffer,
10 ll anti-FLAG M2-agarose was added and immunoprecipitation
was conducted for 1 h by rotation at 4°C. Beads were washed three
times with IP/MS buffer and three times with water and stored at
20°C until MS analysis. In case of THP-1 monocytes, 30 × 106
cells were transiently transfected with the TREM2-TEVFlag cDNA
construct. Upon overnight incubation at 37°C, cells were spun
down and media were processed as described above to give
samples for mass spectrometry. Control samples were generated
using either HEK293 Flp-In cells or THP-1 cells transiently trans-
fected with an empty expression vector (EV; pcDNA5/FRT/TO).
MS analysis was performed using a 4800 MALDI TOF/TOF
analyzer (Applied Biosystems) essentially as described previously
(Fukumori et al, 2010). Immunoprecipitated peptides were eluted
from the beads using 0.3% trifluoroacetic acid (TFA) in 50%
acetonitrile and saturated with a-cyano-4-hydroxy cinnamic acid.
The dissolved samples were dried on a stainless plate and subjected
to MALDI-TOF MS analysis.
Statistics
The data were analyzed using GraphPad Prism 5 (GraphPad Soft-
ware, Inc.) and in SPSS IBM, version 20.0. Group comparisons
in the levels of sTREM2 (Fig 2C) or in phagocytosis assays
(Fig 3) were analyzed by one-way ANOVA test followed by
Dunnett’s or Tukey’s post hoc tests for pairwise comparisons,
respectively. All tests were 2-tailed, and statistical significance
was set to P < 0.05.
Expanded View for this article is available online.
Acknowledgements
This work was supported by the Deutsche Forschungsgemeinschaft (DFG)
within the framework of the Munich Cluster for Systems Neurology (EXC
1010 SyNergy), the DFG research unit FOR 2290 (Understanding intramem-
brane proteolysis), and the Cure Alzheimer’s fund. This project has received
funding from the Innovative Medicines Initiative 2 Joint Undertaking under
grant agreement No 115976. This Joint Undertaking receives support from
the European Union’s Horizon 2020 research and innovation program and
ª 2017 The Authors EMBO Molecular Medicine Vol 9 | No 10 | 2017
Kai Schlepckow et al Cleavage of TREM2 after histidine 157 EMBO Molecular Medicine
1363
EFPIA. We would like to thank Axel Imhof for help with the mass spectrome-
try. Human monocytic THP-1 cells were kindly provided by Roche (Basel,
Switzerland). We also thank Marc Suarez-Calvet for valuable help in statisti-
cal analyses.
Author contributions
CH, KS, and GK designed the study and interpreted the results with additional
help from HS and SFL. KS performed most experiments. Mass spectrometry
was carried out by AF and KS. RF generated monoclonal antibodies. CH wrote
the manuscript with input of all co-authors.
Conflict of interest
C.H. is an advisor of F. Hoffmann-La Roche. C.H., G.K, and K.S. filed a patent
(EP16180844) for the use of TREM2 cleavage modulators.
References
Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers
R, Kang SS, Xu H et al (2015) Apolipoprotein E is a ligand for triggering
receptor expressed on myeloid cells 2 (TREM2). J Biol Chem 290:
26043 – 26050
Bailey CC, DeVaux LB, Farzan M (2015) The triggering receptor expressed on
myeloid cells 2 binds apolipoprotein E. J Biol Chem 290: 26033 – 26042
Black RA (2002) Tumor necrosis factor-alpha converting enzyme. Int J
Biochem Cell Biol 34: 1 – 5
Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, Fenoglio C,
Piaceri I, Archetti S, Bonvicini C et al (2014) Heterozygous TREM2
mutations in frontotemporal dementia. Neurobiol Aging 35: 934 e937 – 910
Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh
RH, Ravits J, Simpson E, Appel SH et al (2014) TREM2 variant p. R47H as a
risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol 71:
449 – 453
Cai XD, Golde TE, Younkin SG (1993) Release of excess amyloid beta protein
from a mutant amyloid beta protein precursor. Science 259: 514 – 516
Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-
Pelfrey C, Lieberburg I, Selkoe DJ (1992) Mutation of the beta-amyloid
precursor protein in familial Alzheimer’s disease increases beta-protein
production. Nature 360: 672 – 674
Colonna M, Wang Y (2016) TREM2 variants: new keys to decipher Alzheimer
disease pathogenesis. Nat Rev Neurosci 17: 201 – 207
Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee
J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N et al (2014)
Investigating the role of rare heterozygous TREM2 variants in Alzheimer’s
disease and frontotemporal dementia. Neurobiol Aging 35: 726 e711 – 726
e729
Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY,
Freedman SB, Folmer B, Goldbach E, Holsztynska EJ et al (2001)
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels
in brain. J Neurochem 76: 173 – 181
Fukumori A, Fluhrer R, Steiner H, Haass C (2010) Three-amino acid spacing of
presenilin endoproteolysis suggests a general stepwise cleavage of
gamma-secretase-mediated intramembrane proteolysis. J Neurosci 30:
7853 – 7862
Glebov K, Wunderlich P, Karaca I, Walter J (2016) Functional involvement of
gamma-secretase in signaling of the triggering receptor expressed on
myeloid cells-2 (TREM2). J Neuroinflammation 13: 17
Guerreiro R, Hardy J (2013) TREM2 and neurodegenerative disease. N Engl J
Med 369: 1569 – 1570
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E,
Cruchaga C, Sassi C, Kauwe JS, Younkin S et al (2013) TREM2 variants in
Alzheimer’s disease. N Engl J Med 368: 117 – 127
Haass C, Hung AY, Schlossmacher MG, Teplow DB, Selkoe DJ (1993) beta-
Amyloid peptide and a 3-kDa fragment are derived by distinct cellular
mechanisms. J Biol Chem 268: 3021 – 3024
Haass C, Koo EH, Capell A, Teplow DB, Selkoe DJ (1995a) Polarized sorting of
beta-amyloid precursor protein and its proteolytic products in MDCK cells
is regulated by two independent signals. J Cell Biol 128: 537 – 547
Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L,
Selkoe DJ (1995b) The Swedish mutation causes early-onset Alzheimer’s
disease by beta-secretase cleavage within the secretory pathway. Nat Med
1: 1291 – 1296
Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier
LL (2006) Cutting edge: inhibition of TLR and FcR responses in
macrophages by triggering receptor expressed on myeloid cells (TREM)-2
and DAP12. J Immunol 177: 2051 – 2055
Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson
P, Ohrfelt A, Blennow K, Hardy J, Schott J et al (2016) Increased
The paper explained
Problem
A central role of microglial function in disease pathogenesis is strongly
supported by the identification of sequence variants in the triggering
receptor expressed on myeloid cells 2 (TREM2) that are associated
with an increased risk for several neurodegenerative disorders. Most
of the functionally investigated mutations are located within the
Ig-like domain of TREM2. Misfolding of this domain, retention, and
consequently reduced shedding appear to be a common read-out of
at least some of these variants. Although many sequence variants
were found within the Ig-like domain, genetic studies also identified
sequence variants within the stalk region and such mutants are unli-
kely to affect folding of the Ig-like domain. Since mutations in the
stalk region may rather affect the efficacy and precision of ADAM-
mediated shedding, we determined the TREM2 cleavage site. More-
over, modulation of TREM2 shedding, for example, by its selective
inhibition, may be an innovative therapeutic approach, for which
knowledge of the exact cleavage site is absolutely required.
Results
TREM2 is shed by proteases of the ADAM (a disintegrin and metallo-
proteinase domain containing protein) family C-terminal to histidine
157, a position where an AD-associated coding variant has been
discovered (p.H157Y) in the Han Chinese population. Opposite to the
characterized mutations within the Ig-like domain, such as p.T66M
and p.Y38C, the p.H157Y variant within the stalk region leads to
enhanced shedding of TREM2. Elevated ectodomain shedding
reduces cell surface full-length TREM2 and lowers TREM2-dependent
phagocytosis.
Impact
Two seemingly opposite cellular effects of TREM2 variants, namely
reduced versus enhanced shedding, result in similar phenotypic
outcomes by reducing cell surface TREM2. Moreover, these findings
may open the opportunity to therapeutically modulate TREM2 func-
tion by selectively blocking access of ADAM proteases to the cleavage
site between histidine 157 and serine 158. In contrast to blocking
ADAM 10/17 activity with conventional protease inhibitors, this
approach would be selective and avoid cleavage inhibition of numer-
ous ADAM10/17 substrates.
EMBO Molecular Medicine Vol 9 | No 10 | 2017 ª 2017 The Authors
EMBO Molecular Medicine Cleavage of TREM2 after histidine 157 Kai Schlepckow et al
1364
cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease.
Mol Neurodegener 11: 3
Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G,
Margevicius D, Karlo JC, Sousa GL et al (2015) TREM2 deficiency eliminates
TREM2+ inflammatory macrophages and ameliorates pathology in
Alzheimer’s disease mouse models. J Exp Med 212: 287 – 295
Jiang T, Tan L, Chen Q, Tan MS, Zhou JS, Zhu XC, Lu H, Wang HF, Zhang YD,
Yu JT (2016) A rare coding variant in TREM2 increases risk for Alzheimer’s
disease in Han Chinese. Neurobiol Aging 42: 217.e1 – 217.e3
Jonsson T, Stefansson K (2013) TREM2 and neurodegenerative disease. N Engl
J Med 369: 1568 – 1569
Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E,
Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F et al (2014)
TREM2 mutations implicated in neurodegeneration impair cell surface
transport and phagocytosis. Sci Transl Med 6: 243ra286
Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X, Focke
C, Deussing M, Suarez-Calvet M, Mazaheri F et al (2017) The FTD-like
syndrome causing TREM2 T66M mutation impairs microglia function,
brain perfusion, and glucose metabolism. EMBO J 36: 1837 – 1853
Klunemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De
Bleecker JL, Rossor MN, Marienhagen J, Klein HE et al (2005) The genetic
causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and
TREM2. Neurology 64: 1502 – 1507
Kober DL, Alexander-Brett JM, Karch CM, Cruchaga C, Colonna M, Holtzman MJ,
Brett TJ (2016) Neurodegenerative disease mutations in TREM2 reveal a
functional surface and distinct loss-of-function mechanisms. eLife 5: e20391
Lichtenthaler SF, Haass C, Steiner H (2011) Regulated intramembrane
proteolysis–lessons from amyloid precursor protein processing. J
Neurochem 117: 779 – 796
Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D (2014) Neuroinflammation:
the role and consequences. Neurosci Res 79: 1 – 12
Ma J, Zhou Y, Xu J, Liu X, Wang Y, Deng Y, Wang G, Xu W, Ren R, Liu X et al
(2014) Association study of TREM2 polymorphism rs75932628 with late-
onset Alzheimer’s disease in Chinese Han population. Neurol Res 36:
894 – 896
Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer
amyloid precursor derivatives stimulated by activation of muscarinic
acetylcholine receptors. Science 258: 304 – 307
Paradowska-Gorycka A, Jurkowska M (2013) Structure, expression pattern and
biological activity of molecular complex TREM-2/DAP12. Hum Immunol 74:
730 – 737
Park JS, Ji IJ, An HJ, Kang MJ, Kang SW, Kim DH, Yoon SY (2015) Disease-
associated mutations of TREM2 alter the processing of N-linked
oligosaccharides in the Golgi apparatus. Traffic 16: 510 – 518
Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM,
Fenoglio C, Galimberti D, Borroni B, Cruchaga C (2016) Cerebrospinal fluid
soluble TREM2 is higher in Alzheimer disease and associated with
mutation status. Acta Neuropathol 131: 925 – 933
Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ,
Lomen-Hoerth C, Kertesz A, Bigio EH et al (2013) TREM2 in
neurodegeneration: evidence for association of the p. R47H variant with
frontotemporal dementia and Parkinson’s disease. Mol Neurodegener 8: 19
Saftig P, Lichtenthaler SF (2015) The alpha secretase ADAM10: a metalloprotease
with multiple functions in the brain. Prog Neurobiol 135: 1 – 20
Shirotani K, Tomioka M, Kremmer E, Haass C, Steiner H (2007) Pathological
activity of familial Alzheimer’s disease-associated mutant presenilin can be
executed by six different gamma-secretase complexes. Neurobiol Dis 27:
102 – 107
Song W, Hooli B, Mullin K, Jin SC, Cella M, Ulland TK, Wang Y, Tanzi R,
Colonna M (2017) Alzheimer’s disease-associated TREM2 variants exhibit
either decreased or increased ligand-dependent activation. Alzheimers
Dement 13: 381 – 387
Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM,
Morris JC, Levin J, Danek A, Ewers M, Haass C et al (2016a) Early changes
in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after
amyloid deposition and neuronal injury. Sci Transl Med 8: 369ra178
Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A,
Alcolea D, Fortea J, Lleo A, Blesa R, Gispert JD et al (2016b) sTREM2
cerebrospinal fluid levels are a potential biomarker for microglia activity
in early-stage Alzheimer’s disease and associate with neuronal injury
markers. EMBO Mol Med 8: 466 – 476
Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS (1996)
Metabolism of the “Swedish” amyloid precursor protein variant in neuro2a
(N2a) cells. Evidence that cleavage at the “beta-secretase” site occurs in
the golgi apparatus. J Biol Chem 271: 9390 – 9397
Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K (1980)
Establishment and characterization of a human acute monocytic
leukemia cell line (THP-1). Int J Cancer 26: 171 – 176
Ulrich JD, Holtzman DM (2016) TREM2 function in Alzheimer’s disease and
neurodegeneration. ACS Chem Neurosci 7: 420 – 427
Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM (2016)
Microglial genes regulating neuroinflammation in the progression of
Alzheimer’s disease. Curr Opin Neurobiol 36: 74 – 81
Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S,
Krishnan GM, Sudhakar S, Zinselmeyer BH et al (2015) TREM2 lipid sensing
sustains the microglial response in an Alzheimer’s disease model. Cell 160:
1061 – 1071
Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE,
Shi Y, Gilfillan S et al (2016) TREM2-mediated early microglial response
limits diffusion and toxicity of amyloid plaques. J Exp Med 213:
667 – 675
Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J (2013)
Sequential proteolytic processing of the triggering receptor expressed on
myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-
secretase-dependent intramembranous cleavage. J Biol Chem 288:
33027 – 33036
Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel
I, Kleinberger G, Haass C (2016) TREM2 deficiency reduces the efficacy of
immunotherapeutic amyloid clearance. EMBO Mol Med 8: 992 –1004
Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M (2016) TREM2 binds to
apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates
uptake of amyloid-beta by microglia. Neuron 91: 328 – 340
Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M,
Baddeley D, Grutzendler J (2016) TREM2 haplodeficiency in mice and
humans impairs the microglia barrier function leading to decreased
amyloid compaction and severe axonal dystrophy. Neuron 90: 724 – 739
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
ª 2017 The Authors EMBO Molecular Medicine Vol 9 | No 10 | 2017
Kai Schlepckow et al Cleavage of TREM2 after histidine 157 EMBO Molecular Medicine
1365
